“Traders stay up on ‘smart’ drugs”
A growing number of businessmen and women seeking an edge over colleagues and competitors are taking modafinil, a drug designed to treat narcolepsy, a disorder that causes people suddenly to fall asleep.
– James Dean, The Times
“My score went up from 8/10 to 9/10”
“Most of us want to reach our true potential. We might drink a cup of coffee to stay awake and alert, or go for a run, to feel on top of the job. So where’s the harm in a pill – a “smart drug” – that can do the same thing?”
– Susan Watts, BBC News
“THE DRUG DOES WORK”
At Cambridge over the summer, many students were taking pills to help their concentration. Ed Cumming was among them
– Ed Cumming, Intelligent Life Magazine
“It’s Wake-Up Time“
But modafinil isn’t just for soldiers and sick people anymore. This year, Cephalon submitted to the FDA a supplemental application that would give physicians a free hand to prescribe Provigil for lesser sleep problems, such as shift-work drowsiness. Even without that approval, the drug is attracting a wider market: Truckers, students, and others pulling all-nighters account for a growing portion of Provigil’s $200 million in annual sales.
– Richard Martin, Wired.com
“How Many Silicon Valley Startup Executives Are Hopped Up On Provigil?”
What’s so funny is that entrepreneurs apparently aren’t interested in typical drugs – instead they find the one that gives them a mental and stamina advantage. Perhaps some enterprising venture capitalist will start requiring founders of their companies to get a prescription in order to close on an investment.
– Michael Arrington, Tech Crunch
“Cognitive enhancement – All on the mind”
“Earlier this year, Nature, one of the world’s leading scientific journals, carried out an informal survey of its (mostly scientific) readers. One in five of the 1,400 people who responded said they had taken Ritalin, Provigil [Modafinil brand name in the USA] or beta blockers (drugs that can have an anti-anxiety effect) for non-medical reasons. They used them to stimulate focus, concentration or memory. Of that one in five, 62% had taken Ritalin and 44% Provigil [Modafinil brand name in the USA].”
— The Economist